NeuFlow is an AI-powered medical device software that quantitatively analyzes Signal Intensity Gradient (SIG), a hemodynamic digital biomarker derived from Time-of-Flight Magnetic Resonance Angiography (TOF-MRA), to assess cerebrovascular health and evaluate the risk of cerebrovascular diseases.
As populations age and chronic diseases become more prevalent, the incidence of cerebrovascular conditions such as stroke and cerebral aneurysm continues to rise worldwide. At the same time, healthcare systems are shifting from treatment-oriented approaches toward prevention and early risk management. However, conventional MRI/MRA-based cerebrovascular examinations primarily focus on identifying structural abnormalities such as stenosis, occlusion, and aneurysms, making it difficult to objectively evaluate latent cerebrovascular risks in patients who are classified as “normal.” As a result, there remains a significant unmet need for quantitative biomarkers that can identify high-risk individuals before disease onset and support preventive healthcare strategies.
NeuFlow was developed to address these challenges. Based on over 15 years of research and development, the company has established proprietary SIG technology that transforms conventional TOF-MRA images into quantitative cerebrovascular data. Unlike traditional hemodynamic assessment methods that require additional imaging procedures such as Phase-Contrast MRI (PC-MR) or computationally intensive CFD simulations, NeuFlow can analyze the entire cerebral vasculature within approximately 10 minutes using only standard TOF-MRA images. This enables clinicians to quantitatively assess cerebrovascular health and identify potential high-risk individuals even when no structural abnormalities are detected.
The software also provides AI-assisted automated analysis and generates patient-friendly cerebrovascular health reports, helping improve clinical workflow efficiency while enhancing patient understanding and engagement. Recently, NeuFlow has expanded its capabilities with AI-based cerebral aneurysm detection functionality and is further advancing toward aneurysm rupture risk prediction and stroke risk assessment technologies.
NeuFlow has obtained both FDA 510(k) clearance and Korean medical device approval and is supported by internationally recognized quality and security standards, including ISO 13485, ISO 27001 series certifications, and HIPAA-compliant processes. The software is currently deployed in more than 30 healthcare institutions across South Korea, including neurology clinics, general hospitals, and university hospitals, with over 10,000 clinical use cases and more than 15,000 accumulated cerebrovascular imaging datasets. The company continues to strengthen its clinical evidence through collaborations with leading institutions such as Seoul National University Hospital, Ulsan University Hospital, Seoul Metropolitan Government–Seoul National University Boramae Medical Center, and Jeonbuk National University Hospital.
Globally, MediIMG is expanding its presence through collaborations with Brown University and Rhode Island Hospital in the United States, leveraging its FDA clearance to enter the U.S. market. The company is also actively pursuing partnerships and proof-of-concept projects in Southeast Asia, particularly in Indonesia and Singapore. Looking ahead, NeuFlow aims to evolve into a comprehensive preventive healthcare platform by integrating Brain Health Scores, AI-based risk prediction models, chronic disease analytics, and digital biomarkers, ultimately delivering personalized cerebrovascular health management solutions worldwide.